[go: up one dir, main page]

MX2019009063A - Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. - Google Patents

Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.

Info

Publication number
MX2019009063A
MX2019009063A MX2019009063A MX2019009063A MX2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A MX 2019009063 A MX2019009063 A MX 2019009063A
Authority
MX
Mexico
Prior art keywords
fusion proteins
making
factor
methods
same
Prior art date
Application number
MX2019009063A
Other languages
English (en)
Inventor
Seth Chhabra Ekta
Kulman John
Liu Tongyao
t peters Robert
Liu Zhiqian
Van Der Flier Arjan
R Light David
ISMAIL Ayman
Original Assignee
Bioverativ Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioverativ Therapeutics Inc filed Critical Bioverativ Therapeutics Inc
Publication of MX2019009063A publication Critical patent/MX2019009063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción proporciona proteínas de fusión del factor IX (FIX) que comprenden al menos un resto heterólogo, tal como un XTEN. La presente descripción describe además métodos para preparar y utilizar las proteínas de fusión del FIX.
MX2019009063A 2017-01-31 2018-01-31 Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas. MX2019009063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762452826P 2017-01-31 2017-01-31
PCT/US2018/016277 WO2018144623A1 (en) 2017-01-31 2018-01-31 Factor ix fusion proteins and methods of making and using same

Publications (1)

Publication Number Publication Date
MX2019009063A true MX2019009063A (es) 2019-10-21

Family

ID=61193175

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009063A MX2019009063A (es) 2017-01-31 2018-01-31 Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.

Country Status (19)

Country Link
US (1) US20210238259A1 (es)
EP (1) EP3576762A1 (es)
JP (1) JP2020505424A (es)
KR (1) KR20190112763A (es)
CN (1) CN110831613A (es)
AR (1) AR110871A1 (es)
AU (1) AU2018215092A1 (es)
BR (1) BR112019015569A2 (es)
CA (1) CA3051862A1 (es)
CL (1) CL2019002155A1 (es)
CR (1) CR20190389A (es)
EA (1) EA201991768A1 (es)
IL (1) IL268234A (es)
MA (1) MA47416A (es)
MX (1) MX2019009063A (es)
PH (1) PH12019501765A1 (es)
SG (1) SG11201906788XA (es)
TW (1) TW201831521A (es)
WO (1) WO2018144623A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3774841A1 (en) 2018-08-27 2021-02-17 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN112175088B (zh) * 2019-07-02 2023-03-28 江苏晟斯生物制药有限公司 改进的fix融合蛋白、缀合物及其应用
CN113817759B (zh) * 2020-07-10 2023-06-02 南京吉迈生物技术有限公司 修饰的因子ix、组合物、方法及其在基因治疗中的应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3684546D1 (de) 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
JP3045539B2 (ja) 1989-02-21 2000-05-29 ワシントン ユニバーシティ 改変型生殖ホルモン
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
CA2288429C (en) 1991-03-15 2006-04-25 Synergen, Inc. Pegylation of polypeptides
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
BR9808584A (pt) 1997-03-14 2000-05-23 Idec Pharma Corp Processo para integrar genes em sìtios especìficos em células de mamìferos via recombinação homóloga e vetores para obter os mesmos
EP2298355A3 (en) 2000-04-12 2011-06-29 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002226028A1 (en) 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
CN1547608A (zh) 2001-09-04 2004-11-17 Ĭ��ר�����޹�˾ 经修饰的因子ix
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
ES2821832T3 (es) 2004-11-12 2021-04-27 Bayer Healthcare Llc Modificación de FVIII dirigida al sitio
KR20080071119A (ko) 2005-08-12 2008-08-01 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP2423306A1 (en) 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
EP2068905A4 (en) 2006-09-14 2009-12-30 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US7700734B2 (en) 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof
SI2369005T1 (sl) 2007-06-21 2013-09-30 Technische Universitet Muenchen Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
CN104004739A (zh) 2007-10-15 2014-08-27 北卡罗来纳-查佩尔山大学 半衰期延长的人因子ix变体
CN102065887A (zh) 2008-04-16 2011-05-18 拜耳医药保健有限公司 因子ix的定点修饰
CA2721683A1 (en) 2008-04-16 2009-11-12 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof
AR071478A1 (es) 2008-04-17 2010-06-23 Baxter Healthcare Sa Peptidos de bajo peso molecular con actividad procoagulante para el tratamiento de pacientes con deficiencia de factor v (fv), fvii, fviii, fx y/o fxi
EP2444491B1 (en) 2008-04-21 2016-11-16 Novo Nordisk Healthcare Ag Hyperglycosylated human coagulation factor IX
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3581579A1 (en) 2009-02-03 2019-12-18 Amunix Pharmaceuticals, Inc. Extended recombinant polypeptides and compositions comprising same
LT2440241T (lt) 2009-06-08 2017-10-10 Amunix Operating Inc. Augimo hormonų polipeptidai ir jų gamybos bei panaudojimo būdai
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
EP2470670A4 (en) * 2009-08-24 2013-07-10 Amunix Operating Inc COAGULATION FACTOR VII COMPOSITIONS AND METHODS OF PREPARATION AND USE THEREOF
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
EP2506868B1 (en) 2009-12-06 2017-11-15 Bioverativ Therapeutics Inc. Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
ES3050283T3 (en) 2010-07-09 2025-12-19 Bioverativ Therapeutics Inc Factor ix polypeptides and methods of use thereof
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
SG10201913893XA (en) 2012-07-11 2020-03-30 Bioverativ Therapeutics Inc Factor viii complex with xten and von willebrand factor protein, and uses thereof
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
HK1248162A1 (zh) * 2015-08-03 2018-10-12 Bioverativ Therapeutics Inc. 因数ix融合蛋白以及其制备及使用方法

Also Published As

Publication number Publication date
CN110831613A (zh) 2020-02-21
TW201831521A (zh) 2018-09-01
EA201991768A1 (ru) 2020-01-22
IL268234A (en) 2019-09-26
CR20190389A (es) 2019-11-26
PH12019501765A1 (en) 2020-03-16
EP3576762A1 (en) 2019-12-11
SG11201906788XA (en) 2019-08-27
AU2018215092A1 (en) 2019-08-29
MA47416A (fr) 2019-12-11
KR20190112763A (ko) 2019-10-07
CA3051862A1 (en) 2018-08-09
US20210238259A1 (en) 2021-08-05
JP2020505424A (ja) 2020-02-20
BR112019015569A2 (pt) 2020-03-17
WO2018144623A1 (en) 2018-08-09
CL2019002155A1 (es) 2020-02-21
AR110871A1 (es) 2019-05-08

Similar Documents

Publication Publication Date Title
PH12018500252A1 (en) Factor ix fusion protiens and methods of making and using same
ZA202308519B (en) Anti-vegf protein compositions and methods for producing the same
CY1124806T1 (el) Αντισωματα enanti-cd40 και χρησεις αυτων
AU2018351050A8 (en) Compositions and methods for selective protein degradation
MX2019007020A (es) Anticuerpos il-11.
MX2019007021A (es) Anticuerpos il-11ra.
PH12019500540A1 (en) Anti-pd-1 antibodies and their uses
EP4585229A3 (en) Means and method for preparing viral vectors and uses of same
MY198059A (en) Anti-ox40 antibodies and their uses
EP4389889A3 (en) Compositions and methods for editing rna
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
PH12019501765A1 (en) Factor ix fusion proteins and methods of making and using same
EP3503911A4 (en) COMPOSITIONS CONTAINING HYBRID ALBUMIN PROTEIN AND ANALOGUES THEREOF, PROCESSES FOR THE PRODUCTION AND USE OF THE SAME
WO2019147947A3 (en) Engineered proteins and methods of use
HK40010491A (en) Compositions containing fusion protein of albumin and analogs thereof, methods for making and using the same